Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Neoadjuvant concurrent chemoradiotherapy
PROCEDURE
2 trials
Sponsors
Samsung Medical Center
, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Conditions
Esophageal Carcinoma
Neoadjuvant Therapy
Stage IIIA Non-small Cell Lung Cancer
Phase 2
Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients
NCT03053856
Samsung Medical Center
Stage IIIA Non-small Cell Lung Cancer
Start: 2017-02-14
End: 2021-08-13
Target: 37
Updated: 2017-02-15
Unknown Phase
Adaptive Neoadjuvant Therapy for Esophageal Cancer
Enrolling by invitation
NCT06990178
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Esophageal Carcinoma, Neoadjuvant Therapy
Start: 2028-03-01
End: 2028-03-31
Target: 43
Updated: 2025-05-25
Related Papers
Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results.
Journal of Clinical Oncology
2019-05-20
5 citations